BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Allegra CJ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, Johnston P, Klein P, Behan K, O'Connell MJ, Levitt R. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol. 2002;20:1735-1743. [PMID: 11919229 DOI: 10.1200/jco.2002.07.080] [Cited by in Crossref: 133] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Popat S, Wort R, Houlston RS. Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance. BMC Cancer 2006;6:150. [PMID: 16753067 DOI: 10.1186/1471-2407-6-150] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
2 Zhao HY, Ma GW, Zou BY, Li M, Lin SX, Zhao LP, Guo Y, Huang Y, Tian Y, Xie D, Zhang L. Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patients. Onco Targets Ther 2014;7:1301-10. [PMID: 25114572 DOI: 10.2147/OTT.S65067] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
3 Cuneo KC, Morgan MA, Griffith KA, Hawkins PG, Greenson JK, Ben-Josef E, Lawrence TS, Zalupski MM. Prognostic Value of c-MET Expression in Patients With Pancreatic Cancer Receiving Adjuvant and Neoadjuvant Chemoradiation Therapy. Int J Radiat Oncol Biol Phys 2018;100:490-7. [PMID: 29229329 DOI: 10.1016/j.ijrobp.2017.10.030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
4 Sinicrope FA, Rego RL, Foster NR, Thibodeau SN, Alberts SR, Windschitl HE, Sargent DJ. Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers. Clin Cancer Res 2008;14:4128-33. [PMID: 18593990 DOI: 10.1158/1078-0432.CCR-07-5160] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
5 Egeland EV, Flatmark K, Nesland JM, Flørenes VA, Mælandsmo GM, Boye K. Expression and clinical significance of Wee1 in colorectal cancer. Tumour Biol 2016;37:12133-40. [PMID: 27220319 DOI: 10.1007/s13277-016-5081-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
6 Debucquoy A, Goethals L, Libbrecht L, Perneel C, Geboes K, Ectors N, McBride WH, Haustermans K. Molecular and clinico-pathological markers in rectal cancer: a tissue micro-array study. Int J Colorectal Dis. 2009;24:129-138. [PMID: 19050903 DOI: 10.1007/s00384-008-0608-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
7 Jourdan F, Sebbagh N, Comperat E, Mourra N, Flahault A, Olschwang S, Duval A, Hamelin R, Flejou JF. Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch 2003;443:115-21. [PMID: 12802583 DOI: 10.1007/s00428-003-0833-z] [Cited by in Crossref: 88] [Cited by in F6Publishing: 78] [Article Influence: 4.9] [Reference Citation Analysis]
8 Hahnvajanawong C, Chaiyagool J, Seubwai W, Bhudhisawasdi V, Namwat N, Khuntikeo N, Sripa B, Pugkhem A, Tassaneeyakul W. Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. World J Gastroenterol 2012;18:3955-61. [PMID: 22912546 DOI: 10.3748/wjg.v18.i30.3955] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
9 Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology. 2009;137:1270-1279. [PMID: 19577568 DOI: 10.1053/j.gastro.2009.06.053] [Cited by in Crossref: 193] [Cited by in F6Publishing: 185] [Article Influence: 16.1] [Reference Citation Analysis]
10 Cao DZ, Ou XL, Yu T. The association of p53 expression levels with clinicopathological features and prognosis of patients with colon cancer following surgery. Oncol Lett 2017;13:3538-46. [PMID: 28521456 DOI: 10.3892/ol.2017.5929] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Park JM, Huang S, Wu TT, Foster NR, Sinicrope FA. Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy. Cancer Biol Ther. 2013;14:100-107. [PMID: 23192274 DOI: 10.4161/cbt.22954] [Cited by in Crossref: 86] [Cited by in F6Publishing: 80] [Article Influence: 9.6] [Reference Citation Analysis]
12 Walter RFH, Werner R, Wessolly M, Mairinger E, Borchert S, Schmeller J, Kollmeier J, Mairinger T, Hager T, Bankfalvi A, Christoph DC, Eberhardt WEE, Plönes T, Aigner C, Schmid KW, Wohlschlaeger J, Mairinger FD. Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53. J Oncol 2018;2018:1986982. [PMID: 30112000 DOI: 10.1155/2018/1986982] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
13 Sinicrope FA, Rego RL, Okumura K, Foster NR, O'Connell MJ, Sargent DJ, Windschitl HE. Prognostic impact of bim, puma, and noxa expression in human colon carcinomas. Clin Cancer Res. 2008;14:5810-5818. [PMID: 18794091 DOI: 10.1158/1078-0432.CCR-07-5202] [Cited by in Crossref: 51] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
14 Soong R, Shah N, Salto-Tellez M, Tai BC, Soo RA, Han HC, Ng SS, Tan WL, Zeps N, Joseph D. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol. 2008;19:915-919. [PMID: 18245778 DOI: 10.1093/annonc/mdm599] [Cited by in Crossref: 96] [Cited by in F6Publishing: 71] [Article Influence: 7.4] [Reference Citation Analysis]
15 Abdallah EA, Fanelli MF, Buim ME, Machado Netto MC, Gasparini Junior JL, Souza E Silva V, Dettino AL, Mingues NB, Romero JV, Ocea LM. Thymidylate synthase expression in circulating tumor cells: a new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients. Int J Cancer. 2015;137:1397-1405. [PMID: 25721610 DOI: 10.1002/ijc.29495] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
16 Glasgow SC, Yu J, Carvalho LP, Shannon WD, Fleshman JW, McLeod HL. Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. Br J Cancer 2005;92:259-64. [PMID: 15655543 DOI: 10.1038/sj.bjc.6602330] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
17 Morikawa T, Kuchiba A, Liao X, Imamura Y, Yamauchi M, Qian ZR, Nishihara R, Sato K, Meyerhardt JA, Fuchs CS. Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. Int J Cancer. 2012;131:1169-1178. [PMID: 22038927 DOI: 10.1002/ijc.26495] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 4.4] [Reference Citation Analysis]
18 Lassmann S, Hennig M, Rosenberg R, Nährig J, Schreglmann J, Krause F, Poignee-Heger M, Nekarda H, Höfler H, Werner M. Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up. Int J Colorectal Dis. 2006;21:238-247. [PMID: 16132996 DOI: 10.1007/s00384-005-0767-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
19 Katkoori VR, Suarez-Cuervo C, Shanmugam C, Jhala NC, Callens T, Messiaen L, Posey J 3rd, Bumpers HL, Meleth S, Grizzle WE, Manne U. Bax expression is a candidate prognostic and predictive marker of colorectal cancer. J Gastrointest Oncol 2010;1:76-89. [PMID: 22811811 DOI: 10.3978/j.issn.2078-6891.2010.019] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
20 Mairinger FD, Vollbrecht C, Flom E, Christoph DC, Schmid KW, Kollmeier J, Popper HH, Mairinger T, Walter RFH. Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma. Oncotarget 2017;8:37502-10. [PMID: 28415584 DOI: 10.18632/oncotarget.16398] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
21 Ayiomamitis GD, Notas G, Zaravinos A, Zizi-Sermpetzoglou A, Georgiadou M, Sfakianaki O, Kouroumallis E. Differences in telomerase activity between colon and rectal cancer. Can J Surg 2014;57:199-208. [PMID: 24869613 DOI: 10.1503/cjs.031312] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
22 Yoon HH, Orrock JM, Foster NR, Sargent DJ, Smyrk TC, Sinicrope FA. Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. PLoS One 2012;7:e42274. [PMID: 22879926 DOI: 10.1371/journal.pone.0042274] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 7.4] [Reference Citation Analysis]
23 Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Chun HK, Lee WY, Park YS. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer. Med Oncol 2010;27:1277-85. [PMID: 19949897 DOI: 10.1007/s12032-009-9374-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
24 Mokarram P, Albokashy M, Zarghooni M, Moosavi MA, Sepehri Z, Chen QM, Hudecki A, Sargazi A, Alizadeh J, Moghadam AR, Hashemi M, Movassagh H, Klonisch T, Owji AA, Łos MJ, Ghavami S. New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targets. Autophagy 2017;13:781-819. [PMID: 28358273 DOI: 10.1080/15548627.2017.1290751] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 18.8] [Reference Citation Analysis]
25 Nanni O, Volpi A, Frassineti GL, De Paola F, Granato AM, Dubini A, Zoli W, Scarpi E, Turci D, Oliverio G, Gambi A, Amadori D. Role of biological markers in the clinical outcome of colon cancer. Br J Cancer 2002;87:868-75. [PMID: 12373601 DOI: 10.1038/sj.bjc.6600569] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 1.9] [Reference Citation Analysis]
26 Kostopoulos I, Karavasilis V, Karina M, Bobos M, Xiros N, Pentheroudakis G, Kafiri G, Papakostas P, Vrettou E, Fountzilas G. Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy. BMC Cancer. 2009;9:339. [PMID: 19775480 DOI: 10.1186/1471-2407-9-339] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
27 Bai H, Wang R, Cheng W, Shen Y, Li H, Xia W, Ding Z, Zhang Y. Evaluation of Concordance Between Deficient Mismatch Repair and Microsatellite Instability Testing and Their Association with Clinicopathological Features in Colorectal Cancer. Cancer Manag Res 2020;12:2863-73. [PMID: 32425600 DOI: 10.2147/CMAR.S248069] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
28 Negri FV, Campanini N, Camisa R, Pucci F, Bui S, Ceccon G, Martinelli R, Fumagalli M, Losardo PL, Crafa P, Bordi C, Cascinu S, Ardizzoni A. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br J Cancer 2008;98:143-7. [PMID: 18087284 DOI: 10.1038/sj.bjc.6604131] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
29 Jung HA, Kim HJ, Maeng CH, Park SH, Lee J, Park JO, Park YS, Lim HY, Kang WK. Changes in the mean corpuscular volume after capecitabine treatment are associated with clinical response and survival in patients with advanced gastric cancer. Cancer Res Treat. 2015;47:72-77. [PMID: 25143051 DOI: 10.4143/crt.2013.172] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
30 Rego RL, Foster NR, Smyrk TC, Le M, O'Connell MJ, Sargent DJ, Windschitl H, Sinicrope FA. Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer 2010;102:165-72. [PMID: 19997103 DOI: 10.1038/sj.bjc.6605473] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 5.2] [Reference Citation Analysis]